Back to Trial Watch
    Clinical Trial Landscape Overview
    Landscape AnalysisIndustry Trends

    Neurodegenerative / Cancer Trial Landscape; Context & Why Current Week Was Light

    December 1, 2025
    7 min read

    Observations from 24 Nov – 1 Dec 2025

    Ongoing Clinical Trials Tracking

    Alzheimer's Disease

    No new major U.S. trials launched this week. Ongoing large studies such as amyloid-removal (pre-symptomatic) and NK-cell therapy trials remain active. (e.g. AHEAD Study, plus previous autologous NK cell-therapy trials); but nothing newly initiated.

    Breast Cancer / Colon Cancer

    No fresh trial launches. Several ongoing trials continue recruitment or follow-up.

    Cancers Beyond the Mainstream

    (e.g. pancreatic FGFR-mutated cancer): While there was a telehealth-based pancreatic cancer trial announced recently (outside our core disease-focus), it signals a growing trend: remote/hybrid trial participation models, which may reshape future clinical research accessibility and data collection dynamics.

    Why This is Important for Kitsa

    Telehealth and Hybrid Trial Models
    1

    Ongoing Momentum

    Even in weeks with few new launches, ongoing trials maintain momentum; valuable for "watch + track" sections to show up-to-date relevance.

    2

    Diversifying Modalities

    Growing experimentation with therapy modality (radioligand, cell-therapy, gut-targeted small molecules, telehealth trials) shows the clinical research field is diversifying.

    3

    Kitsa's Mission Alignment

    This aligns with Kitsa's mission to support advanced, complex, and next-gen trials across emerging therapeutic areas.

    4

    Dynamic Tracking Need

    Underlines the need for a fluid "Trial Watch + Pipeline Tracker" on Kitsa's website: not just new launches, but ongoing high-promise trials, innovations in trial design, and emerging therapeutic mechanisms.

    Key Takeaways

    • •Light weeks in trial launches don't mean reduced clinical research activity; momentum continues in ongoing studies
    • •The therapeutic landscape is rapidly evolving with novel modalities and delivery approaches
    • •Remote and hybrid trial models signal major accessibility improvements for future clinical research
    • •Continuous tracking of both new launches and ongoing trials provides comprehensive industry intelligence

    Stay updated on the latest trial developments

    Keep exploring

    Recommended next